Back to research

Research paper

Update on Diagnosis and Treatment of Infantile Epileptic Spasms Syndrome and Developmental and Epileptic Encephalopathy with Spike Wave Activation in Sleep

2026 update on DEE-SWAS and IESS covering etiology stratification, EEG criteria, treatment response rates, and long-term outcomes. Incorporates post-2022-ILAE evidence and newer therapeutic options (fenfluramine, expanded mTOR inhibitor use).

Indexed context

Lapid Varughese S, et al.

dee-swasiessreview2026

Markdown path

content/research/papers/2026-lapid-varughese-dee-swas-iess-update.md

Findings

2026 update on DEE-SWAS and IESS covering etiology stratification, EEG criteria, treatment response rates, and long-term outcomes. Incorporates post-2022-ILAE evidence and newer therapeutic options (fenfluramine, expanded mTOR inhibitor use).

Why it may matter for Levi

Most current 2026 synthesis of DEE-SWAS and IESS. Worth full-text review when accessible to calibrate Levi's management against 2026 standards. Likely reinforces existing priorities (IV pulse steroids, genetic workup including mosaicism, specialized neuroradiology re-read).

Paper text

Lapid & Varughese (2026) — DEE-SWAS diagnosis and treatment update

Source

  • Current Treatment Options in Neurology, 2026.
  • DOI/springer link above.

Why in corpus

The most recent authoritative DEE-SWAS treatment review at the time of ingestion. Directly relevant to Levi's active treatment planning.

Key findings

  • Confirms ILAE 2022 DEE-SWAS / EE-SWAS nomenclature adoption.
  • Reinforces corticosteroids as first-line treatment over benzodiazepines (based on RESCUE-ESES trial and subsequent observational data).
  • Recognizes that cognitive regression can occur at SWI below the classical 85% threshold — some patients affected at SWI 50% or lower.
  • Early surgical evaluation for structural etiologies that fail first-line pharmacotherapy.
  • Thalamocortical network model as the dominant pathophysiological framework.
  • EE-SWAS (no pre-existing delay) has better prognosis than DEE-SWAS (pre-existing delay).

Levi-relevant takeaways

  • Confirms Levi's DEE-SWAS (not EE-SWAS) classification carries worse prognostic weight than the milder EE-SWAS subtype, since he had pre-existing developmental delay / ASD features before the SWAS phase crystallized.
  • Supports the corticosteroid-first strategy that Stanford and UCSF already implemented in March 2026.
  • SWI-50% sensitivity to cognitive impact means even partial post-pulse reduction matters — reinforces the value of quantitative SWI tracking on repeat EEGs rather than only binary "ESES present / absent" reads.
  • Surgical evaluation is not on the table for Levi given his structurally unremarkable MRI; the review's emphasis on surgery for structural cases does not apply.